Randomized trial of molnupiravir or placebo in patients hospitalized with Covid-19
Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-
IN, a clinical trial evaluating molnupiravir in patients hospitalized with Covid-19. Methods We
conducted a randomized, placebo-controlled, double-blind phase 2/3 trial in patients 18
years old and older requiring in-hospital treatment for laboratory-confirmed Covid-19 with
symptom onset 10 or fewer days before randomization. Participants were randomly …
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe-
IN, a clinical trial evaluating molnupiravir in patients hospitalized with Covid-19. Methods We
conducted a randomized, placebo-controlled, double-blind phase 2/3 trial in patients 18
years old and older requiring in-hospital treatment for laboratory-confirmed Covid-19 with
symptom onset 10 or fewer days before randomization. Participants were randomly …
以上显示的是最相近的搜索结果。 查看全部搜索结果